BioLineRx
BLRX | NASDAQ
$1.19
-$0.11 (-8.46%)
At close: Nov 16, 2026, 3:59 PM ET
$1.16
-$0.03 (-2.39%)
After-hours:
Nov 16, 2026, 7:30 PM ET
BioLineRx Company Profile
Company profile explainedCompany Profile
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.
Key Executives
| Name | Position |
|---|---|
| Philip A. Serlin | Chief Executive Officer |
| Mali Zeevi | Chief Financial Officer |
| Ella Sorani | Chief Development Officer |
| John Lacey | Head of Corporation Communications & Investor Relations |
| Raziel Fried | Treasurer & Budgetary Control Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 23, 2026 | 6-K | Filing |
| Oct 02, 2026 | EFFECT | Filing |
| Oct 02, 2026 | 424B3 | Filing |
| Sep 25, 2026 | F-1 | Filing |
| Sep 24, 2026 | 6-K | Filing |
| Sep 10, 2026 | 6-K | Filing |
| Sep 09, 2026 | D | Filing |
| Aug 31, 2026 | 424B5 | Filing |
| Aug 31, 2026 | 6-K | Filing |
| Aug 31, 2026 | 6-K | Filing |
BioLineRx
| Country | Israel |
| IPO Date | Jul 27, 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Philip A. Serlin |
Contact Details
Modi’in Technology Park Hevel Modi'in,
HM 7177871 Israel
Stock Details
| Ticker Symbol | BLRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001498403 |
| CUSIP Number | 09071M304 |
| ISIN Number | US09071M3043 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove BLRX